518 related articles for article (PubMed ID: 31044341)
1. Radiofluorinated GPC3-Binding Peptides for PET Imaging of Hepatocellular Carcinoma.
Li Y; Zhang J; Gu J; Hu K; Huang S; Conti PS; Wu H; Chen K
Mol Imaging Biol; 2020 Feb; 22(1):134-143. PubMed ID: 31044341
[TBL] [Abstract][Full Text] [Related]
2. Imaging the expression of glypican-3 in hepatocellular carcinoma by PET.
Wang Z; Han YJ; Huang S; Wang M; Zhou WL; Li HS; Wang QS; Wu HB
Amino Acids; 2018 Feb; 50(2):309-320. PubMed ID: 29204748
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and preclinical evaluation of a novel probe [
Mo C; Sun P; Liang H; Chen Z; Wang M; Fu L; Huang S; Tang G
Bioorg Chem; 2024 Jun; 147():107352. PubMed ID: 38640719
[TBL] [Abstract][Full Text] [Related]
4. Glypican-3-targeting F(ab')2 for 89Zr PET of hepatocellular carcinoma.
Sham JG; Kievit FM; Grierson JR; Chiarelli PA; Miyaoka RS; Zhang M; Yeung RS; Minoshima S; Park JO
J Nucl Med; 2014 Dec; 55(12):2032-7. PubMed ID: 25359880
[TBL] [Abstract][Full Text] [Related]
5. Glypican-3-targeted 89Zr PET imaging of hepatocellular carcinoma.
Sham JG; Kievit FM; Grierson JR; Miyaoka RS; Yeh MM; Zhang M; Yeung RS; Minoshima S; Park JO
J Nucl Med; 2014 May; 55(5):799-804. PubMed ID: 24627434
[TBL] [Abstract][Full Text] [Related]
6. SPECT Imaging of Hepatocellular Carcinoma Detection by the GPC3 Receptor.
Xu H; Tang Y; Zhao Y; Wang F; Gao X; Deng D; Gu Y
Mol Pharm; 2021 May; 18(5):2082-2090. PubMed ID: 33797932
[TBL] [Abstract][Full Text] [Related]
7. Low glucose metabolism in hepatocellular carcinoma with GPC3 expression.
Li YC; Yang CS; Zhou WL; Li HS; Han YJ; Wang QS; Wu HB
World J Gastroenterol; 2018 Jan; 24(4):494-503. PubMed ID: 29398870
[TBL] [Abstract][Full Text] [Related]
8. Site-Specifically Conjugated Single-Domain Antibody Successfully Identifies Glypican-3-Expressing Liver Cancer by Immuno-PET.
Fayn S; King AP; Gutsche NT; Duan Z; Buffington J; Olkowski CP; Fu Y; Hong J; Sail D; Baidoo KE; Swenson RE; Cheloha RW; Ho M; Choyke PL; Escorcia FE
J Nucl Med; 2023 Jul; 64(7):1017-1023. PubMed ID: 36997331
[TBL] [Abstract][Full Text] [Related]
9. The development of a Glypican-3-specific binding peptide using
Qin Y; Cheng S; Li Y; Zou S; Chen M; Zhu D; Gao S; Wu H; Zhu L; Zhu X
Biomater Sci; 2020 Oct; 8(20):5656-5665. PubMed ID: 32896851
[TBL] [Abstract][Full Text] [Related]
10. Identification of a Glypican-3-Binding Peptide for In Vivo Non-Invasive Human Hepatocellular Carcinoma Detection.
Qin Z; Wang J; Wang Y; Wang G; Wang X; Zhou Z; Liu G; Gao S; Zhu L
Macromol Biosci; 2017 Apr; 17(4):. PubMed ID: 27862961
[TBL] [Abstract][Full Text] [Related]
11. Development and
Ma XH; Wang S; Liu SY; Chen K; Wu ZY; Li DF; Mi YT; Hu LB; Chen ZW; Zhao XM
World J Gastroenterol; 2019 Jun; 25(24):3030-3043. PubMed ID: 31293339
[TBL] [Abstract][Full Text] [Related]
12. GPC3-targeted immunoPET imaging of hepatocellular carcinomas.
An S; Zhang D; Zhang Y; Wang C; Shi L; Wei W; Huang G; Liu J
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2682-2692. PubMed ID: 35147737
[TBL] [Abstract][Full Text] [Related]
13. Peptide Binder to Glypican-3 as a Theranostic Agent for Hepatocellular Carcinoma.
Lin F; Clift R; Ehara T; Yanagida H; Horton S; Noncovich A; Guest M; Kim D; Salvador K; Richardson S; Miller T; Han G; Bhat A; Song K; Li G
J Nucl Med; 2024 Apr; 65(4):586-592. PubMed ID: 38423788
[TBL] [Abstract][Full Text] [Related]
14. Glypican-3 targeted delivery of
Labadie KP; Ludwig AD; Lehnert AL; Hamlin DK; Kenoyer AL; Sullivan KM; Daniel SK; Mihailovic TN; Sham JG; Orozco JJ; Yeung RS; Chen DL; Wilbur DS; Miyaoka RS; Park JO
Sci Rep; 2021 Feb; 11(1):3731. PubMed ID: 33580090
[TBL] [Abstract][Full Text] [Related]
15. Imaging of hepatocellular carcinoma patient-derived xenografts using ⁸⁹Zr-labeled anti-glypican-3 monoclonal antibody.
Yang X; Liu H; Sun CK; Natarajan A; Hu X; Wang X; Allegretta M; Guttmann RD; Gambhir SS; Chua MS; Cheng Z; So SK
Biomaterials; 2014 Aug; 35(25):6964-71. PubMed ID: 24836949
[TBL] [Abstract][Full Text] [Related]
16. Novel Glypican-3-Binding Peptide for in Vivo Hepatocellular Carcinoma Fluorescent Imaging.
Zhu D; Qin Y; Wang J; Zhang L; Zou S; Zhu X; Zhu L
Bioconjug Chem; 2016 Mar; 27(3):831-9. PubMed ID: 26850086
[TBL] [Abstract][Full Text] [Related]
17. Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate.
Waaijer SJ; Giesen D; Ishiguro T; Sano Y; Sugaya N; Schröder CP; de Vries EG; Lub-de Hooge MN
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217763
[TBL] [Abstract][Full Text] [Related]
18. PET imaging of hepatocellular carcinoma by targeting tumor-associated endothelium using [
Lu Q; Long Y; Fan K; Shen Z; Gai Y; Liu Q; Jiang D; Cai W; Wan C; Lan X
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4000-4013. PubMed ID: 35763056
[TBL] [Abstract][Full Text] [Related]
19. Radiosynthesis and biological evaluation of fluorine-18 labeled N-acetylgalactosamine derivative [
Sun P; Han Y; Zhu Y; Hu K; Huang S; Tan J; Wang M; Wu H; Tang G
Nucl Med Biol; 2020; 88-89():1-9. PubMed ID: 32580089
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo characterization of 2-deoxy-2-18F-fluoro-D-mannose as a tumor-imaging agent for PET.
Furumoto S; Shinbo R; Iwata R; Ishikawa Y; Yanai K; Yoshioka T; Fukuda H
J Nucl Med; 2013 Aug; 54(8):1354-61. PubMed ID: 23843565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]